FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
26 mars 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
Community Oncology Services Global Market Report 2024
21 mars 2024 18h54 HE
|
Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The community oncology services...
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
20 mars 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Global Oncologists Market Report 2024: Precision Medicine and Therapeutic Advancements Drive Expansion to $22.72 Billion by 2028
13 mars 2024 12h11 HE
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global oncologists market has grown steadily in...
Global Interventional Oncology Market Anticipates Explosive Growth, Forecasted at $8.06 Billion by 2034 - Regional Insights for Products, Cancer Types, and End-users
12 mars 2024 12h39 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA
07 mars 2024 08h51 HE
|
Curium
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
07 mars 2024 08h51 HE
|
Curium
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
Arvinas to Participate in Upcoming Investor Conferences
04 mars 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
28 févr. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 févr. 2024 07h00 HE
|
Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the...